PANCREATIC CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Precision Cancer Medicine News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

April 18, 2018

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

By Anonymous User anonymous_user_10987

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim analyses and recommendation. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people […]

View full entry

Tags: AM0010, clinical trials, immunotherapy, Interleukin-10, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, pegilodecakin, Precision Cancer Medicine, treatment


Pamrevlumab Awarded "Fast Track" Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

March 5, 2018

Pamrevlumab Awarded “Fast Track” Development Status for Treatment of Patients with Locally Advanced Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase 2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab […]

View full entry

Tags: locally advanced, News Tips and Features, News Tips and Features Other, Pamrevlumab, Pancreatic Cancer, Precision Cancer Medicine, treatment


Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

February 28, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Pancreatic Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology in […]

View full entry

Tags: larotrectinib, News Tips and Features, News Tips and Features Other, Pancreatic Cancer, Precision Cancer Medicine, treatment


Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

February 15, 2018

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

By Anonymous User anonymous_user_10987

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About Liver Cancer Liver cancer, or hepatocellular carcinoma (HCC), is the second most common cause of cancer-related deaths worldwide.2,3 […]

View full entry

Tags: checkpoint inhibitor, hepatocellular cancer, immunotherapy, keytruda, Liver Cancer, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


Keytruda Promising in PD-L1 Esophageal Cancer

February 13, 2018

Keytruda Promising in PD-L1 Esophageal Cancer

By Anonymous User anonymous_user_10987

CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its anti-cancer effects by blocking a specific protein used by cancer […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, gastroesophageal junction cancer, immunotherapy, keytruda, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

October 16, 2017

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

By Anonymous User anonymous_user_10987

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive the most appropriate personalized care. Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in […]

View full entry

Tags: BRAF, Colon Cancer, erbitux, News Tips and Features, News Tips and Features Other, Precision Cancer Medicine, Rectal Cancer, V600E, vemurafenib, Zelboraf


The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

September 25, 2017

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer

By Anonymous User anonymous_user_10987

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, Gastric Cancer, gastro-esophogeal junction cancer, keytruda, metastatic gastric, News Tips and Features, News Tips and Features Other, pembrolizumab, Precision Cancer Medicine


Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

September 18, 2017

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer

By Anonymous User anonymous_user_10987

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer […]

View full entry

Tags: Gastric Cancer, immunotherapy, KEYNOTE-059 programmed death-ligand 1, keytruda, metastatic gastric cancer, News Tips and Features, News Tips and Features Other, PD-L1, pembrolizumab, Precision Cancer Medicine, stomach cancer


View more articles like this
More news and in-depth Gastric Cancer information

CONDITIONS OF THE GI TRACT